# Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

> **NCT00926289** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 894 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Telmisartan
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00926289
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-04
- **Final completion:** —
- **Target enrollment:** 894 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00926289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00926289, "Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00926289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*